Toronto Dominion Bank Buys New Shares in Omnicell, Inc. (NASDAQ:OMCL)

Toronto Dominion Bank purchased a new position in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 688,161 shares of the company's stock, valued at approximately $30,637,000. Toronto Dominion Bank owned 1.49% of Omnicell as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the stock. Point72 Hong Kong Ltd purchased a new position in shares of Omnicell in the 4th quarter valued at $101,000. ProShare Advisors LLC raised its stake in shares of Omnicell by 44.5% in the 4th quarter. ProShare Advisors LLC now owns 13,766 shares of the company's stock valued at $613,000 after acquiring an additional 4,238 shares during the period. Quantedge Capital Pte Ltd purchased a new position in shares of Omnicell in the 4th quarter valued at $3,366,000. Nomura Holdings Inc. raised its stake in shares of Omnicell by 85.0% in the 4th quarter. Nomura Holdings Inc. now owns 106,463 shares of the company's stock valued at $4,740,000 after acquiring an additional 48,906 shares during the period. Finally, Occudo Quantitative Strategies LP purchased a new position in shares of Omnicell in the 4th quarter valued at $286,000. Hedge funds and other institutional investors own 97.70% of the company's stock.

Analyst Ratings Changes

OMCL has been the topic of a number of research reports. StockNews.com raised shares of Omnicell from a "hold" rating to a "buy" rating in a research note on Tuesday. Wells Fargo & Company raised shares of Omnicell from an "equal weight" rating to an "overweight" rating and lifted their price target for the stock from $31.00 to $35.00 in a research note on Wednesday, May 14th. Benchmark dropped their price target on shares of Omnicell from $62.00 to $40.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Finally, JPMorgan Chase & Co. dropped their price target on shares of Omnicell from $44.00 to $36.00 and set a "neutral" rating on the stock in a research note on Thursday, March 20th. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $46.50.

Omnicell Trading Down 5.0%

Shares of Omnicell stock traded down $1.44 during trading on Wednesday, hitting $27.34. The stock had a trading volume of 577,066 shares, compared to its average volume of 561,055. The stock has a 50 day simple moving average of $31.12 and a 200 day simple moving average of $39.10. The company has a quick ratio of 1.22, a current ratio of 1.37 and a debt-to-equity ratio of 0.13. Omnicell, Inc. has a 1 year low of $22.66 and a 1 year high of $55.75. The company has a market capitalization of $1.28 billion, a PE ratio of 101.26, a P/E/G ratio of 7.53 and a beta of 0.78.

Omnicell (NASDAQ:OMCL - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported $0.26 earnings per share for the quarter, topping analysts' consensus estimates of $0.16 by $0.10. Omnicell had a net margin of 1.13% and a return on equity of 3.82%. The business had revenue of $269.67 million during the quarter, compared to analysts' expectations of $260.18 million. During the same period in the previous year, the company earned $0.03 earnings per share. Omnicell's revenue for the quarter was up 9.5% on a year-over-year basis. On average, research analysts expect that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.